380:
437:
53:
As myeloma cells, NSo cells are naturally antibody-producing suspension cells with a lymphoblast morphology. Gene amplification is typically performed using GS-transfected NS0 cells to select for producing cell lines. The GS-NS0 is a heterologous mammalian expression system that allows for the rapid
44:
secreting MOPC21 tumor. From this tumor, the P3K cells were isolated and developed into two cell lines, 289-16 and P3-X63. The 289-16 cell line secreted only light chain and no heavy chain and was renamed NSI/1. Clones from that cell line were isolated and a nonsecreting cell line was identified and
27:
and commercially in the production of therapeutic proteins. The cell line is a cholesterol-dependent cell line that was generated from a subline of NSI/1 which produced only the light chain but no heavy chain.
179:
Sato, JD; Cao, HT; Kayada, Y; Cabot, MC; Sato, GH; Okamoto, T; Welsh, CJ (December 1988). "Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium".
285:
Barnes, Louise M.; Bentley, Catherine M.; Dickson, Alan J. (20 May 2001). "Characterization of the stability of recombinant protein production in the GS-NS0 expression system".
421:
478:
414:
502:
407:
240:
471:
54:
expression of recombinant proteins. Several therapeutic antibody products are produced using the NS0 cell line including
264:
507:
497:
464:
320:
Wurm, Florian M (November 2004). "Production of recombinant protein therapeutics in cultivated mammalian cells".
223:
Galfrè, G; Milstein, C (1981). "[1] Preparation of monoclonal antibodies: Strategies and procedures".
379:
387:
24:
345:
205:
337:
302:
246:
236:
197:
161:
109:
329:
294:
228:
189:
151:
143:
99:
91:
448:
391:
156:
131:
104:
79:
491:
232:
349:
444:
209:
132:"Advances in animal cell recombinant protein production: GS-NS0 expression system"
80:"Advances in animal cell recombinant protein production: GS-NS0 expression system"
147:
95:
59:
55:
20:
341:
306:
165:
113:
250:
201:
365:
193:
436:
298:
37:
333:
130:
M. Barnes, Louise; Bentley, Catherine M.; Dickson, Alan J. (2000).
41:
225:
Preparation of monoclonal antibodies: strategies and procedures
36:
Development of murine neoplasms started with work with the
125:
123:
452:
395:
227:. Methods in Enzymology. Vol. 73. pp. 3–46.
78:
Barnes, LM; Bentley, CM; Dickson, AJ (February 2000).
23:
derived from the nonsecreting murine myeloma used in
472:
415:
182:In Vitro Cellular & Developmental Biology
8:
479:
465:
422:
408:
155:
103:
70:
7:
433:
431:
376:
374:
265:"NS0 Cell Line from murine myeloma"
14:
435:
378:
287:Biotechnology and Bioengineering
1:
451:. You can help Knowledge by
394:. You can help Knowledge by
233:10.1016/0076-6879(81)73054-4
503:Developmental biology stubs
524:
430:
373:
366:Cellosaurus entry for NS0
148:10.1023/A:1008170710003
96:10.1023/A:1008170710003
388:developmental biology
49:Uses in biotechnology
32:Cell line development
322:Nature Biotechnology
40:mice to isolate the
25:biomedical research
508:Cell biology stubs
194:10.1007/bf02624194
498:Rodent cell lines
460:
459:
403:
402:
45:was named NS0/1.
515:
481:
474:
467:
439:
432:
424:
417:
410:
382:
375:
354:
353:
317:
311:
310:
299:10.1002/bit.1059
282:
276:
275:
273:
271:
261:
255:
254:
220:
214:
213:
176:
170:
169:
159:
127:
118:
117:
107:
75:
523:
522:
518:
517:
516:
514:
513:
512:
488:
487:
486:
485:
429:
428:
371:
362:
357:
334:10.1038/nbt1026
319:
318:
314:
284:
283:
279:
269:
267:
263:
262:
258:
243:
222:
221:
217:
178:
177:
173:
129:
128:
121:
77:
76:
72:
68:
51:
34:
12:
11:
5:
521:
519:
511:
510:
505:
500:
490:
489:
484:
483:
476:
469:
461:
458:
457:
440:
427:
426:
419:
412:
404:
401:
400:
383:
369:
368:
361:
360:External links
358:
356:
355:
328:(11): 1393–8.
312:
293:(4): 261–270.
277:
256:
241:
215:
188:(12): 1223–8.
171:
142:(2): 109–123.
136:Cytotechnology
119:
84:Cytotechnology
69:
67:
64:
50:
47:
33:
30:
13:
10:
9:
6:
4:
3:
2:
520:
509:
506:
504:
501:
499:
496:
495:
493:
482:
477:
475:
470:
468:
463:
462:
456:
454:
450:
447:article is a
446:
441:
438:
434:
425:
420:
418:
413:
411:
406:
405:
399:
397:
393:
390:article is a
389:
384:
381:
377:
372:
367:
364:
363:
359:
351:
347:
343:
339:
335:
331:
327:
323:
316:
313:
308:
304:
300:
296:
292:
288:
281:
278:
266:
260:
257:
252:
248:
244:
242:9780121819736
238:
234:
230:
226:
219:
216:
211:
207:
203:
199:
195:
191:
187:
183:
175:
172:
167:
163:
158:
153:
149:
145:
141:
137:
133:
126:
124:
120:
115:
111:
106:
101:
97:
93:
90:(2): 109–23.
89:
85:
81:
74:
71:
65:
63:
61:
57:
48:
46:
43:
39:
31:
29:
26:
22:
18:
453:expanding it
445:cell biology
442:
396:expanding it
385:
370:
325:
321:
315:
290:
286:
280:
268:. Retrieved
259:
224:
218:
185:
181:
174:
139:
135:
87:
83:
73:
52:
35:
19:are a model
16:
15:
492:Categories
66:References
60:eculizumab
56:daclizumab
21:cell line
17:NS0 cells
350:20428452
342:15529164
307:11283909
166:19002973
114:19002973
270:15 July
251:7300683
210:2470410
202:3209588
157:3449689
105:3449689
348:
340:
305:
249:
239:
208:
200:
164:
154:
112:
102:
38:BALB/c
443:This
386:This
346:S2CID
206:S2CID
449:stub
392:stub
338:PMID
303:PMID
272:2018
247:PMID
237:ISBN
198:PMID
162:PMID
110:PMID
58:and
42:IgG1
330:doi
295:doi
229:doi
190:doi
152:PMC
144:doi
100:PMC
92:doi
494::
344:.
336:.
326:22
324:.
301:.
291:73
289:.
245:.
235:.
204:.
196:.
186:24
184:.
160:.
150:.
140:32
138:.
134:.
122:^
108:.
98:.
88:32
86:.
82:.
62:.
480:e
473:t
466:v
455:.
423:e
416:t
409:v
398:.
352:.
332::
309:.
297::
274:.
253:.
231::
212:.
192::
168:.
146::
116:.
94::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.